Neurology · Wakefulness Promoting AgentRegulatory Approvalcommercialmid-term

Hikma's ANDA for Solriamfetol Hydrochloride Receives Approval Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Hikma4 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 6:31:47 PM

Assessment confidence: 73% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Hikma's ANDA for Solriamfetol Hydrochloride receiving Approval Pending status signals a potential shift in the competitive landscape for wakefulness promoting agents. This could impact pricing and market share for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (12 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Hikma's entry on market dynamics and pricing strategies for similar agents. The strongest clinical anchor is Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Wakefulness Promoting Agent, 8 regulatory and 4 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval status indicates Hikma is positioned to enter the market for wakefulness promoting agents, potentially competing with existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG) (FDA). Entity match (hikma); Regulatory pathway relevance (nda). The Approval Pending status indicates that Hikma is close to receiving final approval, which could influence regulatory strategies for other companies in similar therapeutic areas.

Key Risks

Elevated medium regulatory exposure for Hikma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Status Epilepticus Population Study (STEPS)) could weigh on Hikma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Hikma's entry could lead to increased competition, affecting revenue and market positioning for current players in the wakefulness promoting agents market.
Portfolio teams should assess the impact of Hikma's entry on market dynamics and pricing strategies for similar agents.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval decision and potential launch timelines for Hikma's product.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (solriamfetol hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYMORPHONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cognitive Function in Rett Syndrome During Trofinetide Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Status Epilepticus Population Study (STEPS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Contribution of Immersive Virtual Reality to Standardized Rehabilitation Program for Upper Limb Chronic Pain: A Single-Case Experimental Design Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Green synthesis of ZnO nanoparticles using pomegranate husk extract: comparative evaluation of antioxidant, enzyme inhibition, and cytotoxic properties.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma
Solriamfetol Hydrochloride

Commercial impact

medium

Hikma's entry could lead to increased competition, affecting revenue and market positioning for current players in the wakefulness promoting agents market.

Regulatory impact

medium

The Approval Pending status indicates that Hikma is close to receiving final approval, which could influence regulatory strategies for other companies in similar therapeutic areas.

What to watch

Monitor the final approval decision and potential launch timelines for Hikma's product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.